AVG Ventures and Remeditex Ventures have increased their backing of Bellicum Pharmaceuticals to help it raise $34.4m for its Series B round.
Bellicum said the funding would be used to expand clinical development of its leading cellular immunotherapy product candidates targeting leukaemia and prostate cancer.
Last October venture capital-backed biotech business Immune Design collected up to $49m in Series C financing as it continued to develop immune-based therapies for cancer and other chronic conditions.
The Column Group and new investor Topspin Partners led the round, which included an upfront investment of $32.5m.
Existing backers Alta Partners, Versant Ventures, Osage Venture Partners and ProQuest Investments also took part in the financing, while Sanofi-Genzyme BioVentures joined the syndicate as a new investor.
Copyright © 2014 AltAssets